

**EMERGENCY USE AUTHORIZATION (EUA) SUMMARY
SARS-CoV-2 ASSAY
(Infinity BiologiX Clinical Genomics Laboratory)**

For in vitro diagnostic use

Rx only

For use under Emergency Use Authorization (EUA) Only

(The Infinity BiologiX TaqPath SARS-CoV-2 Assay will be performed at Infinity BiologiX LLC laboratories, located at Nelson Biological Sciences, C-Wing, 604 Allison Road, Piscataway, NJ 08854 and 3510 Hopkins Place, Bldg 4, Oakdale, MN 55128, which are certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a and meet requirements to perform high-complexity tests, per the laboratory procedures that were reviewed by the FDA under this EUA).

INTENDED USE

The Infinity BiologiX TaqPath SARS-CoV-2 Assay is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal (throat) swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, and bronchoalveolar lavage (BAL) fluid from individuals suspected of COVID-19 by their healthcare provider.

When determined to be appropriate by a healthcare provider, this test is also for use with saliva specimens that are self-collected at home using the IBX Saliva Collection Kit or that are collected in a healthcare setting by individuals using the Spectrum Solutions SDNA-1000 Saliva Collection Device.

Testing is limited to Infinity BiologiX LLC laboratories, located at Nelson Biological Sciences, C-Wing, 604 Allison Road, Piscataway, NJ 08854 and 3510 Hopkins Place, Bldg 4, Oakdale, MN 55128, which are certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a and meet requirements to perform high-complexity tests.

Results are for the detection and identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Negative results for SARS-CoV-2 RNA from saliva should be confirmed by testing of an alternative specimen type if clinically indicated.

Testing with the Infinity BiologiX TaqPath SARS-CoV-2 Assay is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The assay is intended for use under the Food and Drug Administration's Emergency Use Authorization.

DEVICE DESCRIPTION AND TEST PRINCIPLE

The Infinity BiologiX TaqPath SARS-CoV-2 Assay is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test. The assay uses primers and probes that were developed and validated under the Emergency Use Authorization (EUA) for the TaqPath COVID-19 Combo Kit and are designed to detect RNA from SARS-CoV-2 in respiratory specimens from patients as recommended for testing by public health authority guidelines. This EUA authorizes testing of additional specimen types, including saliva, and use of alternative nucleic acid extraction and amplification systems available to Infinity BiologiX.

Anterior nasal swabs, mid-turbinate nasal swabs, oropharyngeal (throat) swabs and nasopharyngeal swabs and bronchoalveolar lavage fluid should be collected, transported and stored according to standard procedures. Saliva specimens may be collected in a healthcare setting using the Spectrum Solutions SDNA-1000 Saliva Collection Device or be self-collected at home using the IBX Saliva Collection Kit (comprised of the Spectrum Solutions SDNA-1000 Saliva Collection Device and instructions for sample collection and shipment to the testing laboratory). Saliva specimens must be transported and stored at ambient temperature and tested within 56 hours of collection when stored at ambient temperature.

RNA extraction for all specimen types is performed using the PerkinElmer Chemagic 360 automated specimen processing system with the Chemagic Viral DNA/RNA 300 Kit H96. The input sample volume is 300 µL, the elution volume is 50 µL.

Reverse transcriptase-PCR (RT-PCR) is performed using the Applied Biosystems TaqPath COVID-19 Combo Kit with 5 µL of the extracted sample.

INSTRUMENTS USED WITH THE TEST

The Infinity BiologiX TaqPath SARS-CoV-2 Assay is for use with the ThermoFisher Applied Biosystems QuantStudio 5 Real-Time PCR System equipped with software v1.3, or the Applied Biosystems ViiA7 Real-Time PCR System with the Applied Biosystems QuantStudio 5 software v1.3 for data analysis, and Perkin Elmer Chemagic 360 extraction instrument (software v6.3.0.3).

REAGENTS AND MATERIALS

Table 1. Reagents and materials required for use of the Infinity BiologiX TaqPath SARS-CoV-2 Assay

| Reagent | Manufacturer | Catalogue # |
|------------------------------------|-------------------------|-------------|
| Chemagic Viral DNA/RNA 300 Kit H96 | PerkinElmer | CMG-1033-S |
| 96 well Deep Well Plates | PerkinElmer | 43001-0120 |
| TaqPath COVID-19 Combo Kit | ThermoFisher Scientific | A147814 |
| 384 well PCR plate | ThermoFisher Scientific | 4483273 |
| Optical adhesive PCR plate cover | ThermoFisher Scientific | 4311971 |
| Nuclease-free water | -- | -- |
| Ethanol (96-100%) | -- | -- |

CONTROLS

The controls supplied with the ThermoFisher - Applied Biosystems TaqPath COVID-19 Combo Kit are described in **Table 2**.

Table 2. Controls supplied with the Applied Biosystems TaqPath COVID-19 Combo Kit

| Control Type | Purpose | Frequency of Testing |
|----------------------|--|---|
| Negative | To monitor for cross-contamination during RNA extraction and RT-PCR | Once per batch of specimens |
| Positive | To monitor the integrity of the RT-PCR reagents and process | Once per run of RT-PCR |
| Internal (MS2 Phage) | To monitor the integrity of nucleic acid extraction and RT-PCR for each specimen | Added to each specimen and the Negative Control prior to extraction |

In addition to these controls, a No Template Control containing none of the SARS-CoV-2 targets or the Internal Control is included in every PCR run. The results from the controls are interpreted according to the criteria shown in **Table 3**. If the results obtained with the Positive, Negative and No Template Controls do not meet the criteria shown, the results from the entire batch of samples are considered invalid and repeat testing must be performed.

Table 3. Ct values for controls that must be observed to obtain valid results

| Control | Ct Value (Optical Channel) | | | |
|-------------|----------------------------|--------------|--------------|---------------------------|
| | N Gene (VIC) | S Gene (ABY) | ORF1ab (FAM) | MS2 Phage (JUN) |
| Negative | >40 | >40 | >40 | ≤37 |
| Positive | <37 | <37 | <37 | Undetermined ¹ |
| No Template | Undetermined | Undetermined | Undetermined | Undetermined ¹ |
| Internal | Any | Any | Any | <37 |

¹ The MS2 Phage Internal Control is not added to the Positive Control or No Template Control and no signal should be obtained

INTERPRETATION OF RESULTS

The results from testing of patient samples are interpreted according to the criteria described in Table 4.

Table 4. Result interpretation for patient samples

| Ct Value (Optical Channel) | | | | Result Interpretation |
|----------------------------|--------------|--------------|-----------------|-----------------------|
| N Gene (VIC) | S Gene (ABY) | ORF1ab (FAM) | MS2 Phage (JUN) | |
| Undetermined | Undetermined | Undetermined | <37 | Negative |
| Two of three <37 | | | <37 | Positive |
| One of three <37 | | | <37 | Re-test ¹ |
| Undetermined | Undetermined | Undetermined | Undetermined | Re-test ¹ |

¹ Re-test required from the residual extracted sample and by processing a new aliquot of the original sample if volume permits; if the re-test result is the same as the original then report result as “inconclusive”

PERFORMANCE EVALUATION

1) Analytical Sensitivity

The LoD was determined using *in vitro* transcripts from Exact Diagnostics (SARS-CoV-2 Standard) that were diluted in SARS-CoV-2 negative nasopharyngeal swab matrix. An initial estimate of the LoD with the Applied Biosystems QuantStudio 5 Real-Time PCR System was obtained by testing three replicates at each of four different target levels: 1000, 500, 200 and 100 copies/mL. The lowest level at which all three replicates were positive for all three SARS-CoV-2 targets was 200 copies/mL. The estimated LoD was confirmed by testing an additional 20 replicates at the same target level. All 20 replicates produced the expected results for each SARS-CoV-2 target, and the LoD was therefore confirmed to be 200 copies/mL.

To validate use of the Applied Biosystems ViiA7 Real-Time PCR System for PCR amplification, an additional study was performed by testing 20 nasopharyngeal and 10 saliva samples that were each spiked with 400 copies/mL of the Exact Diagnostics SARS-CoV-2 transcripts. Positive results were obtained for each of the samples for all three target genes and the MS2 internal control, demonstrating that the ViiA7 Real-Time PCR system performed similarly to the QuantStudio 5. These results are acceptable.

2) Analytical Specificity

Inclusivity

The Infinity BiologiX TaqPath SARS-CoV-2 Assay is a modification of the previously authorized ThermoFisher Applied Biosystems TaqPath COVID-19 Combo Kit. The assay targets specific genomic regions of the SARS-CoV-2 nucleocapsid (N) gene, spike (S) gene, and ORF1ab region. Inclusivity was demonstrated under the original EUA by mapping the primers and probes to 185 complete SARS-CoV-2 genomes that were available in the GenBank and GISAID (Global Initiative on Sharing All Influenza Data) databases as of March 5, 2020. For all primers and probes, there was 100% homology to each of the SARS-CoV-2 sequences analyzed, with one exception; a single base mismatch (95.6% homology) with the reverse primer for ORF1ab in sequence EPI_ISL_407084

(BetaCoronavirus/Japan/AI/I-004/2020). The mismatch is located at the 5' end of the primer and is not expected to affect test performance

Cross-reactivity

The analytical specificity of the Infinity BiologiX TaqPath SARS-CoV-2 Assay was demonstrated *in silico* under the original EUA for the ThermoFisher Applied Biosystems TaqPath COVID-19 Combo Kit. The analysis included evaluation of the primer and probe homology with the 43 organisms and viruses listed in **Table 5**. Based on this analysis, significant amplification of non-target sequences that could result in cross-reaction (false-positive results) or interference (false-negative results) was considered unlikely to occur.

Table 5. Organisms and viruses evaluated for potential cross-reaction and/or interference with the Applied Biosystems TaqPath COVID-19 Combo Kit

| Viruses | Bacteria |
|-------------------------------------|---|
| Adenovirus | <i>Bacillus anthracis</i> |
| Enterovirus | <i>Bordetella pertussis</i> |
| Human coronavirus 229E | <i>Chlamydomyphila pneumoniae</i> |
| Human coronavirus HKU1 | <i>Chlamydomyphila psittaci</i> |
| Human coronavirus NL63 | <i>Corynebacterium diphtheriae</i> |
| Human coronavirus OC43 | <i>Coxiella burnetii</i> |
| Human Metapneumovirus (hMPV) | <i>Haemophilus influenzae</i> |
| Influenza A, B and C | <i>Legionella</i> (non-pneumophila) |
| MERS-coronavirus | <i>Legionella pneumophila</i> |
| Parainfluenza 1-4 | <i>Leptospira</i> sp. |
| Parechovirus | <i>Moraxella catarrhalis</i> |
| Respiratory Syncytial Virus A and B | <i>Mycobacterium tuberculosis</i> |
| Rhinovirus/Enterovirus | <i>Mycoplasma pneumoniae</i> |
| SARS-coronavirus | <i>Neisseria elongata</i> and <i>Neisseria meningitidis</i> |
| Yeast/Fungus | <i>Pseudomonas aeruginosa</i> |
| <i>Candida albicans</i> | <i>Staphylococcus aureus</i> |
| <i>Pneumocystis jirovecii</i> | <i>Staphylococcus epidermidis</i> |
| | <i>Streptococcus pneumoniae</i> |
| | <i>Streptococcus pyogenes</i> |
| | <i>Streptococcus salivarius</i> |

3) Clinical Evaluation

Nasopharyngeal Swabs

The performance of the Infinity BiologiX TaqPath SARS-CoV-2 Assay with nasopharyngeal swabs was evaluated using contrived specimens composed of leftover nasopharyngeal swab samples that were spiked with SARS-CoV-2 *in vitro* transcripts or human DNA (both Exact Diagnostics). A total of 30 contrived positive and contrived negative samples were tested. A summary of the results of the study is provided in **Tables 6** and **7**. All 30 (100%) contrived negative samples produced the expected results. Of the 30 contrived positive samples, all 30 (100%) produced positive results for the N

and S genes, whereas the ORF1ab target was positive for 25/30 samples (83.3%). No amplification of the ORF1ab target was observed with 1/10 samples (10.0%) at 200 copies/mL and 4/10 samples (40.0%) at 400 copies/mL. According to the result algorithm described in **Table 4**, above, a sample is considered positive for SARS-CoV-2 RNA if amplification is detected with at least two of the three SARS-CoV-2-specific target sequences. The results of the Clinical Evaluation with contrived nasopharyngeal swabs were therefore considered acceptable.

Table 6. Summary of results from the contrived specimen study with nasopharyngeal swabs, stratified by target level and measurand

| Transcript Copies/mL | Number Tested | Analysis | Target (Optical Channel) | | | |
|----------------------|---------------|--------------|--------------------------|--------------|--------------|------------|
| | | | N Gene (VIC) | S Gene (ABY) | ORF1ab (FAM) | MS2 (JUN) |
| 0 | 30 | Positive (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | | Mean Ct (SD) | N/A | N/A | N/A | 24.4 (0.4) |
| 200 | 10 | Positive (%) | 10 (100) | 10 (100) | 9 (100) | 10 (100) |
| | | Mean Ct (SD) | 21.7 (4.3) | 22.1 (6.0) | 19.7 (1.6) | 27.1 (1.2) |
| 400 | 10 | Positive (%) | 10 (100) | 10 (100) | 6 (60.0) | 10 (100) |
| | | Mean Ct (SD) | 27.0 (6.7) | 26.6 (6.8) | 21.1 (2.3) | 26.1 (1.2) |
| 600 | 4 | Positive (%) | 4 (100) | 4 (100) | 4 (100) | 4 (100) |
| | | Mean Ct (SD) | 28.5 (5.2) | 27.2 (4.5) | 27.4 (6.2) | 25.7 (0.9) |
| 800 | 3 | Positive (%) | 3 (100) | 3 (100) | 3 (100) | 3 (100) |
| | | Mean Ct (SD) | 33.0 (1.6) | 30.5 (0.4) | 35.0 (3.9) | 25.0 (0.9) |
| 1000 | 3 | Positive (%) | 3 (100) | 3 (100) | 3 (100) | 3 (100) |
| | | Mean Ct (SD) | 28.8 (6.6) | 27.7 (5.6) | 29.0 (7.3) | 25.8 (1.2) |
| All Positives | 30 | Positive (%) | 30 (100) | 30 (100) | 25 (83.3) | 30 (100) |
| | | Mean Ct (SD) | 26.2 (6.3) | 25.7 (5.1) | 24.2 (6.4) | 26.2 (1.3) |

N/A: Not applicable; SD: Standard Deviation

Table 7. Summary of positive and negative agreement with contrived nasopharyngeal swab specimens

| | | Contrived Specimen Type | | |
|--------------------------|----------|--------------------------------------|----------|-------|
| | | Positive | Negative | Total |
| TaqPath SARS-CoV-2 Assay | Positive | 30 | 0 | 30 |
| | Negative | 0 | 30 | 30 |
| | Total | 30 | 30 | 60 |
| Positive Agreement | | 100% (30/30); 88.7-100% ¹ | | |
| Negative Agreement | | 100% (30/30); 88.7-100% | | |

¹ Two-sided 95% score confidence intervals

Saliva

A study was performed to evaluate the use of saliva as a specimen type for detection of SARS-CoV-2 in patients who are suspected of COVID-19. The study was conducted with symptomatic patients from three ambulatory care centers who were each provided with instructions for self-collection of saliva using the Spectrum Solutions SDNA-1000 Saliva Collection Device. Self-collection of saliva samples was performed under the observation of a healthcare provider who subsequently (within 10 minutes) also collected either a nasopharyngeal or oropharyngeal swab from each patient for parallel testing for

SARS-CoV-2. The swabs were placed in viral transport medium for shipment to the testing laboratory. Both the saliva and swabs were transported at ambient temperature and tested using the Infinity BiologiX Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay within 48 hours of collection. A summary of the results of the study is presented in **Tables 8** and **9**.

There was 100% positive and negative agreement between the results obtained from testing of saliva and those obtained from nasopharyngeal and oropharyngeal swabs. Overall mean Ct values were similar for saliva and either nasopharyngeal or oropharyngeal swabs, there was no correlation between Ct values from different samples from the same patient. Nevertheless, the results support the use of saliva as a specimen type for use with the Infinity BiologiX TaqPath SARS-CoV-2 Assay.

Table 8. Summary of qualitative results obtained from parallel testing of nasopharyngeal and oropharyngeal swab samples and saliva from patients suspected of COVID-19

| | | Nasopharyngeal Swab | | |
|--------------------|----------|--------------------------------------|----------|-------|
| | | Positive | Negative | Total |
| Saliva | Positive | 26 | 0 | 26 |
| | Negative | 0 | 27 | 27 |
| | Total | 26 | 27 | 53 |
| Positive Agreement | | 100% (26/26); 87.1-100% ¹ | | |
| Negative Agreement | | 100% (27/27); 87.5-100% | | |
| | | Oropharyngeal Swab | | |
| | | Positive | Negative | Total |
| Saliva | Positive | 4 | 0 | 4 |
| | Negative | 0 | 3 | 3 |
| | Total | 4 | 3 | 7 |
| Positive Agreement | | 100% (4/4); 51.0-100% ¹ | | |
| Negative Agreement | | 100% (3/3); 43.9-100% | | |
| | | Nasopharyngeal or Oropharyngeal Swab | | |
| | | Positive | Negative | Total |
| Saliva | Positive | 30 | 0 | 30 |
| | Negative | 0 | 30 | 30 |
| | Total | 30 | 30 | 60 |
| Positive Agreement | | 100% (30/30); 88.7-100% ¹ | | |
| Negative Agreement | | 100% (30/30); 88.7-100% | | |

¹ Two-sided 95% score confidence intervals

Table 9. Summary of results obtained from parallel testing of nasopharyngeal and oropharyngeal swab samples and saliva from patients suspected of COVID-19, stratified by measurand

| Number of Patients | Sample Type | Analysis | Target (Optical Channel) | | | |
|--------------------|-------------|--------------|--------------------------|--------------|--------------|------------|
| | | | N Gene (VIC) | S Gene (ABY) | ORF1ab (FAM) | MS2 (JUN) |
| 26 NP positive | NP swab | Positive (%) | 26 (100) | 26 (100) | 26 (100) | 26 (100) |
| | | Mean Ct (SD) | 24.4 (4.0) | 24.5 (3.9) | 23.6 (3.7) | 24.3(2.6) |
| | Saliva | Positive (%) | 26 (100) | 26 (100) | 26 (100) | 26 (100) |
| | | Mean Ct (SD) | 23.5 (6.2) | 24.6 (6.0) | 23.6 (5.7) | 26.0 (4.1) |
| 27 NP negative | NP swab | Positive (%) | 0 (0) | 0 (0) | 0 (0) | 27 (100) |
| | | Mean Ct (SD) | N/A | N/A | N/A | 24.4 (1.2) |
| | Saliva | Positive (%) | 0 (0) | 0 (0) | 0 (0) | 27 (100) |
| | | Mean Ct (SD) | N/A | N/A | N/A | 25.0 (1.9) |
| 4 OP positive | OP swab | Positive (%) | 4 (100) | 4 (100) | 4 (100) | 4 (100) |
| | | Mean Ct (SD) | 24.7 (4.0) | 24.3 (3.9) | 23.5 (4.4) | 25.4 (1.8) |
| | Saliva | Positive (%) | 4 (100) | 4 (100) | 4 (100) | 4 (100) |
| | | Mean Ct (SD) | 22.0 (7.1) | 22.3 (7.2) | 21.4 (7.1) | 29.6 (5.6) |
| 3 OP negative | OP Swab | Positive (%) | 0 (0) | 0 (0) | 0 (0) | 23.5 (1.5) |
| | | Mean Ct (SD) | N/A | N/A | N/A | 3 (100) |
| | Saliva | Positive (%) | 0 (0) | 0 (0) | 0 (0) | 3 (100) |
| | | Mean Ct (SD) | N/A | N/A | N/A | 23.1 (1.4) |

NP: Nasopharyngeal; OP: Oropharyngeal; N/A: Not applicable; SD: Standard Deviation

Clinical Confirmation

The first 5 positive and first 5 negative nasopharyngeal specimens as using the Infinity BiologiX TaqPath SARS-CoV-2 Assay were also tested by the New Jersey State Health Department using the previously authorized CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. There was 100% (5/5) positive and negative agreement for the specimens tested. These results are acceptable and support use of the Infinity BiologiX TaqPath SARS-CoV-2 Assay for testing clinical specimens.

4) Simulated Shipping Study with the SDNA-1000 Saliva Collection Device

To support home use of the Spectrum Solutions SDNA-1000 Saliva Collection Device, used as part of the IBX Saliva Collection Kit, a Simulated Shipping Study was performed that was designed to evaluate the effect of temperature variation on the stability of SARS-CoV-2 RNA during transport of saliva specimens. The study was conducted using residual clinical specimens that had previously been reported as SARS-CoV-2 positive or negative using the Infinity BiologiX TaqPath SARS-CoV-2 Assay, and which were stored at -80°C until the start of the study. The SARS-CoV-2 positive specimens were selected based on the Ct values obtained upon initial testing and covered the spectrum of Ct values observed with the assay.

To perform the study, the specimens were thawed and then subjected to the thermal profiles outlined in **Tables 10** and **11** which were intended to simulate the extreme temperature conditions that may be experienced in shipment of specimens during the summer and winter, respectively. At the conclusion of each thermal profile, the samples were retested with the Infinity BiologiX TaqPath SARS-CoV-2 Assay and the results

obtained were compared to those reported upon initial testing at the time the specimens were received. A summary of the mean Ct values observed for each SARS-CoV-2 specific target gene is provided in **Table 12**. The Ct values for each individual sample are presented graphically in **Figure 1**.

Nineteen out of 20 Low Positive samples (95%) and 10/10 High Positive samples were reported as positive after exposure to the summer and winter temperature excursions. The mean and standard deviation of the Ct values for each gene target were similar before and after simulated shipping, with no evidence of significant degradation of the SARS-CoV-2 RNA. All SARS-CoV-2 negative specimens were reported as “negative.”

These results demonstrate that SARS-CoV-2 RNA positive saliva specimens are stable in the SDNA-1000 Saliva Collection Device when exposed to a broad range of temperature conditions. These data support the use of the SDNA-1000 Saliva Collection Device for transport and storage of specimens following home collection of saliva.

Table 10. Summer temperature excursion

| Temperature (°C) | Cycle Period | Time (hours) | |
|------------------|--------------|--------------|-------------------------|
| | | Cycle Period | Total Time ¹ |
| 40 | 1 | 8 | 8 |
| 22 | 2 | 4 | 12 |
| 30 | 3 | 2 | 14 |
| 22 | 4 | 36 | 50 |
| 40 | 5 | 6 | 56 |

¹ Sum of Cycle Periods

Table 11. Winter temperature excursion

| Temperature (°C) | Cycle Period | Time (hours) | |
|------------------|--------------|--------------|-------------------------|
| | | Cycle Period | Total Time ¹ |
| -80 | 1 | 8 | 8 |
| 18 | 2 | 4 | 12 |
| -10 | 3 | 4 | 16 |
| 4 | 4 | 38 | 56 |

¹ Sum of Cycle Periods

Table 12. Summary of results from the Simulated Shipping Study with the SDNA-1000 Saliva Collection Device

| Sample Group | Test Point | N | Mean Ct (Standard Deviation) | | | Positive (%) |
|---------------|---------------------|----|------------------------------|------------------------|------------|--------------|
| | | | N Gene | ORF1ab | S Gene | |
| Negative | T = 0 | 10 | N/A | N/A | N/A | 0 (0) |
| | Summer ¹ | 10 | N/A | N/A | N/A | 0 (0) |
| | Winter ² | 10 | N/A | 38.6 (--) ³ | N/A | 0 (0) |
| Low Positive | T = 0 | 20 | 29.0 (1.9) | 29.3 (2.1) | 29.4 (3.1) | 20 (100) |
| | Summer | 20 | 29.9 (2.4) | 29.3 (2.9) | 29.0 (2.5) | 19 (95) |
| | Winter | 20 | 30.0 (2.4) | 29.1 (2.7) | 28.8 (2.0) | 19 (95) |
| High Positive | T = 0 | 10 | 20.8 (2.2) | 21.3 (1.9) | 20.7 (2.7) | 10 (100) |
| | Summer | 10 | 23.5 (3.5) | 22.3 (3.8) | 22.5 (4.0) | 10 (100) |
| | Winter | 10 | 23.4 (3.3) | 22.2 (3.4) | 22.1 (3.2) | 10 (100) |

N/A: Not Applicable


¹ Testing performed at the conclusion of the thermal excursions described in **Table 10**

² Testing performed at the conclusion of the thermal excursions described in **Table 11**

³ 1 sample gave a Ct value for ORF1ab but no amplification was observed for the other two SARS-CoV-2 targets. Based on the algorithm used for the Infinity BiologiX TaqPath SARS CoV-2 Assay (**Table 4**), at least two targets must have Ct values <37 for a specimen to be called positive for SARS-CoV-2 RNA. Therefore, this sample was recorded as “SARS-CoV-2 RNA Negative.”

⁴ Low Positive: Ct >25 at T= 0 for all targets; High Positive: Ct <25 at T = 0 for all targets

Figure 1. Ct values for each SARS-CoV-2 target gene by sample



Samples 1-10: High Positive (Ct value <25 for each target at T = 0)
 Samples 11-30: Low Positive (Ct value >25 for each target at T = 0)

LIMITATIONS

- Testing of saliva specimens is limited to patients with symptoms of COVID-19.

WARNINGS

- This test has not been FDA cleared or approved.
- This test has been authorized by FDA under an EUA for use by Infinity BiologiX LLC laboratories, located at Nelson Biological Sciences, C-Wing, 604 Allison Road, Piscataway, NJ 08854 and 3510 Hopkins Place, Bldg 4, Oakdale, MN 55128.
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.